A Study to Assess the Efficacy and Safety of Vamorolone in Boys With Duchenne Muscular Dystrophy (DMD)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT03439670 |
Recruitment Status :
Active, not recruiting
First Posted : February 20, 2018
Last Update Posted : September 17, 2020
|
Sponsor:
ReveraGen BioPharma, Inc.
Collaborators:
European Union
Cooperative International Neuromuscular Research Group
Newcastle University
University of Pittsburgh
Information provided by (Responsible Party):
ReveraGen BioPharma, Inc.
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
Recruitment Status : | Active, not recruiting |
---|---|
Estimated Primary Completion Date : | February 24, 2021 |
Estimated Study Completion Date : | August 1, 2021 |
Publications:
Investigator's Brochure, Version 4, Vamorolone (17α,21-dihydroxy-16α-methyl-pregna-1,4,9(11)-triene-3,20-dione) 4% Oral Suspension, ReveraGen BioPharma, Inc., January 10, 2017.
FDA Draft Guidance for Industry: Duchenne muscular dystrophy and related dystrophinopathies: developing drugs for treatment. June 2015.